Member Contact: Richard Allman
Position: Chief Scientific Officer
Industry: Biotech & Pharmaceuticals
Genetic Technologies is a molecular diagnostics company listed on the ASX (GTG) in 2000 and NASDAQ (GENE) in 2005 that offers predictive testing and assessment tools to help physicians proactively manage people’s health.
The Company’s legacy product, BREVAGenplus, was a clinically validated risk assessment test for non-hereditary breast cancer and was first in its class. BREVAGenplus improved upon the predictive power of the first generation BREVAGen test and was designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans.
Genetic Technologies have developed two new cancer risk assessment tests - GeneType for Breast Cancer and GeneType for Colorectal Cancer. The new Breast Cancer test provides substantial improvement over the Company’s legacy breast cancer test BREVAGenplus, by incorporating multiple additional clinical risk factors. This test will provide healthcare providers and their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer.
The Colorectal Cancer test will provide healthcare providers and their patients a 5-year, 10-year, and lifetime risk assessment of the patient developing colorectal cancer.
The Company also has a pipeline of further new tests under development including Type 2 Diabetes, Cardiovascular, Prostate and Melanoma